Clinical Trials
126 trialsAMYLOCARP
Ramsay Générale de Santé
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
MGUS-PET
University of Zurich
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Stanford University
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
BMT
Massachusetts General Hospital
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis
M.D. Anderson Cancer Center
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
Weill Medical College of Cornell University
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Emory University
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
Peking University People's Hospital
Ixazomib Maintenance Study in Patients With AL Amyloidosis
Memorial Sloan Kettering Cancer Center
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
MICA
Brigham and Women's Hospital
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
Memorial Sloan Kettering Cancer Center
A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
Peking University First Hospital
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Teclistamab in Previously Treated AL Amyloidosis
Peking Union Medical College Hospital
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Peking University People's Hospital
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
University of California, San Francisco
DarPAL
Fondazione IRCCS Policlinico San Matteo di Pavia
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
University of Tennessee Graduate School of Medicine
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Peking University People's Hospital
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
First Affiliated Hospital of Wenzhou Medical University
Daratumumab for Patients With Light Chain Amyloidosis
Nanjing University School of Medicine
Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Barbara Ann Karmanos Cancer Institute
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Nanjing University School of Medicine
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis
The Cleveland Clinic
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
Boston Medical Center
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Barbara Ann Karmanos Cancer Institute
Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis
Air Force Military Medical University, China
Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis
Barbara Ann Karmanos Cancer Institute
STARR
Weill Medical College of Cornell University
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
Icahn School of Medicine at Mount Sinai
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis
Peking Union Medical College Hospital
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
University of Tennessee Graduate School of Medicine
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
Northwestern University